SAB Biotherapeutics, Inc. (NASDAQ:SABS)

SAB Biotherapeutics, Inc. SABS

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 3.1

-15.5 %

$ 28.6 M

Market Cap

-0.49

P/E

1. INTRINSIC VALUE

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza.[ Read More ]

The intrinsic value of one SABS stock under the base case scenario is HIDDEN Compared to the current market price of 3.1 USD, SAB Biotherapeutics, Inc. is HIDDEN

SABS Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart SABS

FINANCIALS

Annual
Quarterly

2.24 M REVENUE

Growth Rates

1Year -90.63%

3Years -65.65%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-38.1 M OPERATING INCOME

Growth Rates

1Year -31.67%

3Years -41.82%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-42.2 M NET INCOME

Growth Rates

1Year -146.11%

3Years -45.77%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-25.1 M OPERATING CASH FLOW

Growth Rates

1Year -668.32%

3Years -51.98%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-153 K INVESTING CASH FLOW

Growth Rates

1Year 98.60%

3Years 77.10%

5Years 0.00%

7Years 0.00%

10Years 0.00%

66.8 M FINANCING CASH FLOW

Growth Rates

1Year 95.70%

3Years 95.17%

5Years 0.00%

7Years 0.00%

10Years 0.00%

0 REVENUE

Growth Rates

1Year -90.63%

3Years -65.65%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-11.3 M OPERATING INCOME

Growth Rates

1Year -31.67%

3Years -41.82%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-10.3 M NET INCOME

Growth Rates

1Year -146.11%

3Years -45.77%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-6.29 M OPERATING CASH FLOW

Growth Rates

1Year -668.32%

3Years -51.98%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-1.15 M INVESTING CASH FLOW

Growth Rates

1Year 98.60%

3Years 77.10%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-674 K FINANCING CASH FLOW

Growth Rates

1Year 95.70%

3Years 95.17%

5Years 0.00%

7Years 0.00%

10Years 0.00%

Balance Sheet Decomposition SAB Biotherapeutics, Inc.

83.9 M ASSETS
26.6 M LIABILITIES

Current Assets	58.9 M
Cash & Short-Term Investments	56.6 M
Receivables	0
Other Current Assets	2.34 M
Non-Current Assets	25 M
Long-Term Investments	0
PP&E	24.7 M
Other Non-Current Assets	350 K

Current Liabilities	10.8 M
Accounts Payable	946 K
Short-Term Debt	2.65 M
Other Current Liabilities	7.21 M
Non-Current Liabilities	15.8 M
Long-Term Debt	4.05 M
Other Non-Current Liabilities	11.8 M

EFFICIENCY

Earnings Waterfall SAB Biotherapeutics, Inc.

Revenue	2.24 M
Cost Of Revenue	3.75 M
Gross Profit	-1.51 M
Operating Expenses	40.3 M
Operating Income	-38.1 M
Other Expenses	4.12 M
Net Income	-42.2 M

RATIOS

-67.28% GROSS MARGIN

Averages

1Year -67.28%

3Years 38.75%

5Years 63.25%

7Years 0.00%

10Years 0.00%

-1700.56% OPERATING MARGIN

Averages

1Year -1700.56%

3Years -614.51%

5Years -411.66%

7Years 0.00%

10Years 0.00%

-1884.50% NET MARGIN

Averages

1Year -1884.50%

3Years -663.85%

5Years -445.75%

7Years 0.00%

10Years 0.00%

-73.64% ROE

Averages

1Year -73.64%

3Years -59.74%

5Years 56.16%

7Years 0.00%

10Years 0.00%

-50.27% ROA

Averages

1Year -50.27%

3Years -36.35%

5Years -25.16%

7Years 0.00%

10Years 0.00%

-64.37% ROIC

Averages

1Year -64.37%

3Years -61.97%

5Years 567.69%

7Years 0.00%

10Years 0.00%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis SAB Biotherapeutics, Inc.

Net Income	-42.2 M
Depreciation & Amortization	3.75 M
Capital Expenditures	-197 K
Stock-Based Compensation	2.42 M
Change in Working Capital	2.33 M
Others	8.05 M
Free Cash Flow	-25.3 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets SAB Biotherapeutics, Inc.

Wall Street analysts predict an average 1-year price target for SABS of $6.2 , with forecasts ranging from a low of $3 to a high of $8 .

SABS Lowest Price Target Wall Street Target

3 USD -3.23%

SABS Average Price Target Wall Street Target

6.2 USD 100.00%

SABS Highest Price Target Wall Street Target

8 USD 158.06%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore.

0 USD

CMRA

Overvalued 100.00%

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States.

3.47 USD

PCSA

Undervalued 243.94%

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.

0 USD

FRTX

Overvalued 100.00%

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases.

6.69 USD

THRD

Overvalued 44.96%

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders.

-3.41 USD

CINGW

Overvalued 6910.87%

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.

0.12 USD

ANEB

Overvalued 92.46%

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.

9.65 USD

CVKD

Overvalued 38.35%

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

0.501 USD

MNPR

Overvalued 97.23%

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury.

0.392 USD

UNCY

Overvalued 14.78%

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome.

2.66 USD

QNRX

Undervalued 329.03%

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.

0.000095 USD

CDIO

Overvalued 99.96%

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.

0.852 USD

VRAX

Overvalued 52.40%

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms.

0.198 USD

PXMD

Undervalued 97.71%

6. Ownership

Insider Ownership SAB Biotherapeutics, Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

15.9 K USD 3

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
11 months ago Dec 07, 2023	Bought 1.53 K USD	Sullivan Eddie Joe Chief Executive Officer	+ 1740	0.88 USD
11 months ago Nov 30, 2023	Bought 4.5 K USD	King Michael CHIEF FINANCIAL OFFICER	+ 5000	0.9 USD
11 months ago Nov 29, 2023	Bought 9.84 K USD	Reich Samuel J Executive Chairman	+ 11000	0.8947 USD
2 years ago Sep 13, 2022	Bought 7.3 K USD	HAMILTON CHRISTINE E director, 10 percent owner:	+ 10000	0.7297 USD
2 years ago Sep 07, 2022	Bought 10.3 K USD	Sullivan Eddie Joe CHIEF EXECUTIVE OFFICER	+ 14000	0.7368 USD
3 years ago Oct 26, 2021	Sell 2.2 K USD	Beyer Russell P Chief Financial Officer	- 278	7.9 USD
3 years ago Oct 13, 2021	Bought 5.05 K USD	Katz Ilan director, 10 percent owner:	+ 500	10.105 USD
3 years ago Oct 14, 2021	Bought 10.1 K USD	Reich Samuel J CEO and CFO	+ 1000	10.11 USD
3 years ago Oct 01, 2021	Bought 131 K USD	Spragens Jeffrey G Director	+ 13000	10.07 USD
3 years ago Oct 01, 2021	Bought 10.1 K USD	Katz Ilan director, 10 percent owner:	+ 1000	10.09 USD
3 years ago Jan 14, 2021	Bought 4.17 M USD	Reich Samuel J CEO and CFO	+ 417200	10 USD
3 years ago Jan 14, 2021	Bought 4.17 M USD	Katz Ilan director, 10 percent owner:	+ 417200	10 USD
3 years ago Jan 14, 2021	Bought 4.17 M USD	Big Cypress Holdings LLC CEO and CFO	+ 417200	10 USD

7. News

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. globenewswire.com - 1 week ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / September 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / September 24, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / September 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeu NEW YORK, NY / ACCESSWIRE / September 20, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc. NEW YORK, NY / ACCESSWIRE / September 19, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap NEW YORK, NY / ACCESSWIRE / September 18, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap NEW YORK, NY / ACCESSWIRE / September 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders. accesswire.com - 1 month ago

8. Profile Summary

SAB Biotherapeutics, Inc. SABS

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 28.6 M

Dividend Yield 0.00%

Description SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Contact 2100 East 54th Street North, Sioux Falls, SD, 57104 https://www.sabbiotherapeutics.com

IPO Date Feb. 9, 2021

Employees 57

Officers Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs Dr. Christoph Bausch M.B.A., Ph.D. Executive Vice President & Chief Operating Officer Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director Mr. Samuel J. Reich Chief Executive Officer & Executive Chairman Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer Dr. Alexandra Kropotova M.B.A., M.D. Executive Vice President & Chief Medical Officer

Price Chart SABS

SAB Biotherapeutics, Inc. SABS

Premium Plan

Unlimited Plan